400
Participants
Start Date
July 11, 2024
Primary Completion Date
January 1, 2029
Study Completion Date
August 31, 2034
Vusolimogene Oderparepvec
Genetically modified Herpes Simplex Type 1 Virus.
Nivolumab
Anti-PD-1 Monoclonal Antibody
Nivolumab + Relatlimab
Nivolumab: Anti-PD-1 Monoclonal antibody. Relatlimab: A lymphocyte activation gene-3 (LAG-3) blocking antibody.
Pembrolizumab
A programmed death receptor-1 (PD-1)-blocking antibody indicated.
Single-agent chemotherapy
Dacarbazine, temozolomide, or paclitaxel/albumin-bound paclitaxel.
RECRUITING
Montefiore Medical Center, The Bronx
RECRUITING
Northwell Health, R.J. Zuckerberg Cancer Center, Lake Success
RECRUITING
Stony Brook University Cancer Center, Stony Brook
RECRUITING
Roswell Park Cancer Institute, Buffalo
RECRUITING
UPMC, Pittsburgh
RECRUITING
Thomas Jefferson University, Philadelphia
RECRUITING
Fox Chase Cancer Center, Philadelphia
RECRUITING
MedStar Washington Hospital Center, Washington D.C.
RECRUITING
West Virginia University, Morgantown
RECRUITING
University of North Carolina at Chapel Hill, Chapel Hill
RECRUITING
Duke Cancer Center, Durham
RECRUITING
Winship Cancer Institute, Emory University, Atlanta
RECRUITING
Memorial Cancer Institute at Memorial Regional Hospital, Hollywood
RECRUITING
Moffitt Cancer Center, Tampa
RECRUITING
University of Tennessee, Knoxville
RECRUITING
West Cancer Center and Research Institute, Germantown
RECRUITING
University of Louisville Brown Cancer Center, Louisville
RECRUITING
The Ohio State University- Martha Morehouse Tower, Columbus
RECRUITING
Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion), Detroit
RECRUITING
Corewell Health, Grand Rapids
RECRUITING
University of Iowa, Iowa City
RECRUITING
University of Minnesota, Minneapolis
RECRUITING
Advocate Lutheran General Hospital, Park Ridge
RECRUITING
Northwestern Memorial Hospital, Chicago
RECRUITING
University of Kansas Cancer Center, Westwood
RECRUITING
Texas Oncology, Dallas
RECRUITING
University of Texas Southwestern Medical Center, Dallas
RECRUITING
The University of Texas MD Anderson Cancer Center, Houston
RECRUITING
University of Colorado Hospital - Anschutz Cancer Pavilion, Aurora
RECRUITING
The Melanoma and Skin Cancer Institute, Englewood
RECRUITING
Intermountain Health, Murray
RECRUITING
Huntsman Cancer Institute, Salt Lake City
RECRUITING
St. George Regional Hospital, St. George
RECRUITING
Banner MD Anderson Cancer Center, Gilbert
RECRUITING
The Angeles Clinic and Research Institute, Los Angeles
RECRUITING
USC Norris Comprehensive Cancer Center, Los Angeles
RECRUITING
UCLA Department of Medicine - Hematology/Oncology, Los Angeles
RECRUITING
UC San Diego Moores Cancer Center, La Jolla
RECRUITING
UC Irvine Health, Chao Family Comprehensive Cancer Center, Orange
RECRUITING
San Francisco Oncology Associates, San Francisco
RECRUITING
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
RECRUITING
Stanford Cancer Institute, Palo Alto
RECRUITING
Sutter Medical Group, Sacramento
RECRUITING
Dartmouth Hitchcock Cancer Center, Lebanon
RECRUITING
MD Anderson Cancer Center at Cooper, Camden
RECRUITING
Hackensack University Medical Center, Hackensack
RECRUITING
Morristown Medical Center - Atlantic Health System, Morristown
RECRUITING
Rhode Island Hospital, Providence
RECRUITING
University of Vermont Medical Center, Burlington
Replimune Inc.
INDUSTRY